Shlomi Raz & Paul Daley on Ariadne, ASRI, and Sasha Shulgin’s Legacy | Sasha Centennial

Ariadne is a formerly overlooked therapeutic compound explored by chemist Alexander Shulgin. Despite its potential in managing Parkinson's symptoms, original clinical trials were discontinued due to a lack of commercial support. Decades later, the Alexander Shulgin Research Institute along with Negev Labs are reviving investigation into this molecule, employing modern rigorous clinical standards to evaluate its therapeutic promise. The development of this compound represents a key focus for the Alexander Shulgin Research Institute. Every new clinical trial aimed at understanding Ariadne carries forward the legacy of Sasha Shulgin by applying modern data, intellectual property development and regulatory foresight to substance discovery and evaluation.